~Bengaluru based Urban Primary Health Centre received specialized Godrej Vaccine Refrigerator to safely store covid-19 vaccines.
Bengaluru, 20th May 2021: Godrej & Boyce, the flagship company of the Godrej Group, announced recently that its business, Godrej Appliances, one of India’s leading consumer durables company, has donated a specialized 99-litre vaccine refrigerator to Urban Primary Health Centre, BBMP West Zone, Bengaluru to strengthen their preparedness towards tackling the Covid immunization drive.
Godrej has been partnering the ongoing Covid vaccination drive by the government, with its made in India, advanced cold storage solutions for vaccines and life-saving supplies.
The advanced 99 litre Godrej vaccine refrigerator was recently handed over by representative of Godrej & Boyce Mfg Co. Ltd to Dr. Sujatha S Hiremath, Medical Officer, Urban Primary Health Centre, BBMP West Zone, Bengaluru in a formal ceremony.
This was part of the Godrej & Boyce’s COVID Outreach initiative, under which the brand is donating 40 units of advanced medical refrigerators to various hospitals and public health centres pan India. Godrej & Boyce, the flagship company of the diversified Godrej group, is widely known for its commitment towards nation building and society.
Embassy REIT collaborates with Corporates to Provide Life-Saving ICU Beds, Equipment and Manpower to Government Hospitals in Bengaluru Embassy REIT along with ANZ, Swiss Re, CapitaLand and others mobilize INR 7.3 crores for this initiative; the beneficiaries of these hospitals will receive treatment free of cost.
Bengaluru, May 20, 2021: In response to the Honourable Chief Minister Shri BS Yediyurappa’s appeal for corporates to collaborate in the battle against the Covid-19 pandemic, Embassy Office Parks REIT (‘Embassy REIT’), India’s first listed REIT and the largest in Asia by area, has led a consortium of their Office Park tenants to set-up 69 fully fitted ICU beds, life-saving medical equipment and manpower to operationalize ICUs in 3 government hospitals in Bengaluru.
Embassy REIT, through its Corporate Connect Programme, has mobilized over INR 7.3 crores with corporates partners ANZ, Swiss Re and CapitaLand, amongst others. Embassy REIT managed the initiative to liaise with the Health Department to identify the beneficiary hospitals, shortlisted suppliers for the life-saving medical equipment, and raised funds towards activating this crucial relief initiative towards strengthening the Government’s effort to manage Covid-19.
The hospitals will also benefit from manpower assistance from Doctors for You, Cloud Physicians and LabourNet with the support of Azim Premji Foundation, which will tackle the acute shortage of intensivists, doctors and nurses required to operate the ICUs. The health department will provide ventilators for these hospitals from the Prime Ministers Relief Fund. Currently, 46 of the 69 ICU Beds are in the process of being set-up and operationalized at the Epidemic Diseases Hospital in Indiranagar and Jayanagar General Hospital. The remaining 23 ICU Beds will be finalized in the coming week. The beneficiaries of these hospitals will receive treatment free of cost. In messages from the CM of Karnataka and the Department of Health, Government of Karnataka, the partners were thanked for their contributions towards enhancing the healthcare infrastructure to fight the pandemic. Shri BS Yediyurappa, Honourable Chief Minister, Karnataka, expressed his gratitude towards Embassy REIT and its partners for their support. Embassy REIT had previously donated Modular ICU beds for Covid-19 patients at KC General Hospital during the first wave of the pandemic, which are being used at maximum capacity. Inaugurated by Hon. Chief Minister Shri B.S. Yediyurappa, and Hon. Deputy Chief Minister Dr. Ashwathnarayan C N, the success of state-of-the-art Modular ICUs has led for a call to ramp-up the production of more of them.
Hyderabad, India, 20th May 2021: Bharat Biotech a global leader in vaccine innovation, developing vaccines for infectious diseases, announced today, the quick ramp up of additional manufacturing capacities for COVAXIN®, India’s 1st Indigenous Covid 19 Vaccine at CHIRON BEHRING Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech.
The company plans to produce 200 million doses of COVAXIN® per annum in the good manufacturing practice (GMP) facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. Product availability at Ankleshwar to commence from Q4 2021.
Bharat Biotech had already deployed multiple Production lines at its Hyderabad & Bengaluru campuses, Adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture COVAXIN®. This effectively takes the volumes upto ~ 1 Billion doses per Annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.
ಕೋವಿಡ್ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ಅನಾಥವಾದ ಮಕ್ಕಳ ಪೋಷಣೆಗೆ ಸರ್ಕಾರ ಸಿದ್ದ – ಬಾಧಿತ ಮಕ್ಕಳ ವಸತಿಗಾಗಿ ರೆಸಿಡೆನ್ಸಿಯಲ್ ಶಾಲೆ ಮೀಸಲು – ಸಚಿವೆ ಶಶಿಕಲಾ ಜೊಲ್ಲೆ ಮಹತ್ವದ ಘೋಷಣೆ
ಬೆಂಗಳೂರು ಮೇ.18 – ರಾಜ್ಯದಲ್ಲಿ ಕೋವಿಡ್ ಎರಡನೇ ಅಲೆ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ಪಾಲಕರ ಪೋಷಣೆಯಿಂದ ಅನಾಥರಾದ ಮಕ್ಕಳ ಪುನರ್ವಸತಿ ಕಲ್ಪಿಸಲು ಸರ್ಕಾರ ಸಿದ್ದವಿದ್ದು, 18 ವರ್ಷದೊಳಗಿನ ಮಕ್ಕಳ ಕ್ವಾರೆಂಟೈನ್ ಗಾಗು ಒಂದು ವಸತಿಶಾಲೆ ನಿರ್ಧರಿಸಲಾಗಿದ್ದು, ಅಂಥಹ ಮಕ್ಕಳ ಯಾವುದೇ ಕಾರಣಕ್ಕೂ ಭಯ ಪಡುವ ಅವಶ್ಯಕತೆ ಇಲ್ಲ ಎಂದು ಮಹಿಳಾ ಮತ್ತು ಮಕ್ಕಳ ಕಲ್ಯಾಣ ಸಚಿವೆ ಶ್ರೀಮತಿ ಶಶಿಕಲಾ ಜೊಲ್ಲೆ ಅಭಯ ನೀಡಿದ್ದಾರೆ.
ಕೋವಿಡ್ ಕಾರಣದಿಂದ ಅನಾಥರಾದ ಮಕ್ಕಳ ಕುರಿತು ಮಹಿಳಾ ಮತ್ತು ಮಕ್ಕಳ ಅಭಿವೃದ್ಧಿ ಇಲಾಖೆ ಕೈಗೊಂಡ ಕ್ರಮಗಳ ಕುರಿತು ಮಾಹಿತಿ ನೀಡಿದ ಅವರು, ಕೋವಿಡ್ ನಿಂದ ಬಾಧಿತರಾದ ಮಕ್ಕಳನ್ನು ಗುರುತಿಸಲು ಹಾಗೂ ಪುನರ್ವಸತಿಗೆ ಸರ್ಕಾರ 1098 ಎಂಬ ಸಹಾಯವಾಣಿ ತಂದಿದ್ದು, ಹಿರಿಯ ಐಎಎಸ್ ಅಧಿಕಾರಿ ಮೋಹನ್ ರಾಜ್ ಅವರನ್ನು ನೋಡಲ್ ಅಧಿಕಾರಿಯಾಗಿ ನೇಮಿಸಲಾಗಿದ್ದು, ಇಂಥ ಮಕ್ಕಳಿಗೆ ಕೌಟುಂಬಿಕ ವಾತಾವರಣ ಒದಗಿಸುವುದು ಸಚಿವೆಯಾಗಿ ನನ್ನ ಹಾಗೂ ನಮ್ಮ ಇಲಾಖೆ ಹಾಗೂ ನಮ್ಮ ಸರ್ಕಾರದ ಕರ್ತವ್ಯ ಎಂದರು.
ಮಕ್ಕಳು ಪಾಲಕರ ಪೋಷಣೆಯಿಂದ ವಂಚಿರಾಗುವ ಸಂಧರ್ಭಗಳು
1.ತಂದೆ – ತಾಯಿ ಕೋವಿಡ್ ನಿಂದ ಮೃತರಾದರೆ 2.ತಂದೆ-ತಾಯಿ ಇಬ್ಬರು ಆಸ್ಪತ್ರೆಗೆ ದಾಖಲಾದರೆ
ಕೋವಿಡ್ ನಿಂದ ಒಬ್ಬರು ಮೃತರಾಗಿ ಇನ್ನೊಬ್ಬರು ಆಸ್ಪತ್ರೆಗೆ ದಾಖಲಾದರೆ
ಒಬ್ಬರು ಮೃತರಾಗಿ ಇನ್ನೊಬ್ಬರು ಬೇರೆ ಪ್ರದೇಶದಲ್ಲಿ ವಾಸವಿದ್ದರೆ. ಈ ಮೇಲಿನ ಕಾರಣಗಳಿಂದ ಮಕ್ಕಳು ಅನಾಥರಾದಾಗ ಅವರಿಗೆ ನಾವಿದ್ದೇವೆ ಎಂಬ ಭಾವನೆಯನ್ನು ಮೂಡಿಸಲು ಇಲಾಖೆ ಸಜ್ಜಾಗಿದೆ.
ಇನ್ನು ಸಚಿವೆ ಶಶಿಕಲಾ ಜೊಲ್ಲೆಯವರ ವಿಶೇಷ ಮುತುವರ್ಜಿ ಮೇರೆಗೆ ಕೋವಿಡ್ ಬಾಧಿತ ಅನಾಥ ಮಕ್ಕಳಿಗಾಗಿಯೇ ಹಲವು ಯೋಜನೆಗಳನ್ನು ಜಾರಿಗೆ ತರಲಾಗಿದೆ.
6 ವರ್ಷದೊಳಗಿನ ಮಕ್ಕಳ ಆರೈಕೆಗೆ ವಿಶೇಷ ಕ್ವಾರೆಂಟೈನ್ ಸೌಲಭ್ಯ, ವಿಶೇಷ ದತ್ತು ಸಂಸ್ಥೆಗಳನ್ನು ಗೊತ್ತುಪಡಿಸುವುದು.
7 ರಿಂದ 18 ವರ್ಷದೊಳಗಿನ ಮಕ್ಕಳ ಆರೈಕೆಗೆ ವಿಶೇಷ ಕ್ವಾರೆಂಟೈನ್ ಸೌಲಭ್ಯ ಹಾಗೂ ಪಿಟ್ ಫೆಸಿಲಿಟಿಸ್ ಒದಗಿಸುವುದು
18 ವರ್ಷದವರೆಗಿನ ಮಕ್ಕಳ ಕ್ವಾರೆಂಟೈನ್ ಗಾಗಿ ರೆಸಿಡೆನ್ಸಿಯಲ್ ಮೀಸಲಿಡಲು ತೀರ್ಮಾನ
ಕೋವಿಡ್ ಸೋಂಕಿತ ಮಕ್ಕಳ ಚಿಕಿತ್ಸೆಗೆ ವಿಶೇಷ ಯೋಜನೆ
ಯಾವುದೇ ಲಕ್ಷಣಗಳಿಲ್ಲದ ಕೋವಿಡ್ ಪೀಡಿತ ಮಕ್ಕಳಿಗೆ ವಿಶೇಷ ಪಿಡಿಯಾಟ್ರಿಕ್ ಕೋವಿಡ್ ಕೇರ್ ಸೆಂಟರ್ (CCC) ಗಳಲ್ಲಿ ಚಿಕಿತ್ಸೆ ನೀಡಲು ಅನುಕೂಲವಾಗುವಂತೆ 30 ಜಿಲ್ಲೆಗಳಲ್ಲಿ ಪ್ರತ್ಯೇಕ ಕೋವಿಡ್ ಕೇರ್ ಸೆಂಟರ್ ಸ್ಥಾಪನೆ 2.ಲಕ್ಷಣವುಳ್ಳ ಕೋವಿಡ್ ಸೋಂಕಿತ ಮಕ್ಕಳಿಗೆ ತಾಲೂಕು ಹಾಗೂ ಜಿಲ್ಲಾ ಆಸ್ಪತ್ರೆಯಲ್ಲಿ ಪಿಡಿಯಾಟ್ರಿಕ್ ಕೋವಿಡ್ ಕೇರ್ ಸೆಂಟರ್ ನಲ್ಲಿ ವಿಶೇಷ ಆರೈಕೆ. ಇಲಾಖೆಯಿಂದ ವಿಶೇಷ ಆರೈಕೆದಾರರ ನೇಮಕ
ಕೋವಿಡ್ ಸಂಧರ್ಭದಲ್ಲಿ ನಮ್ಮ ಇಲಾಖೆಯಿಂದ ಕೈಗೊಂಡ ಕ್ರಮಗಳು
ಅಂಗನವಾಡಿ ಫಲಾನುಭವಿಗಳಿಗೆ ಮನೆಮನೆಗೆ ತೆರಳಿ ವಿಶೇಷ ಪೌಷ್ಟಿಕ ಆಹಾರ ವಿತರಣೆ 2.ಅಂಗನವಾಡಿ ಮಕ್ಕಳು, ಗರ್ಭಿಣಿ, ಬಾಣಂತಿಯರ ಆರೋಗ್ಯದ ಮೇಲೆ ವಿಶೇಷ ನಿಗಾ
ಕೋವಿಡ್ ಸೋಂಕಿನಿಂದ ಮರಣಹೊಂದಿದ 12 ಅಂಗನವಾಡಿ ಕಾರ್ಯಕರ್ತೆಯರಿಗೆ 30 ಲಕ್ಷ ರೂಗಳ ಪರಿಹಾರ ಬಿಡುಗಡೆಗೆ ಕ್ರಮ ಕೈಗೊಳ್ಳಲಾಗಿದೆ.
3ನೇ ಅಲೆಯು ಚಿಕ್ಕ ಮಕ್ಕಳಲ್ಲಿಯೇ ಹೆಚ್ಚಾಗಿ ಸೋಂಕು ಕಂಡುಬರುತ್ತದೆ ಎಂದು ತಜ್ಞರು ಎಚ್ಚರಿಸಿದ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ಈಗಾಗಲೇ ನಮ್ಮ ಇಲಾಖೆ ಇದಕ್ಕೆ ಪೂರಕವಾದ ಕ್ರಮಗಳನ್ನು ಕೈಗೊಳ್ಳುತ್ತಿದೆ.
Home-grown VIRANORM’ shows breakthrough results in reduction of NL Ratio and increase of cellular immunity in fight against COVID-19.
The Bengaluru based Khoday Group of Industries has rolled out a first of its kind Ayurvedic Immuno-modulator VIRANORM that helped COVID patients recover quickly in a recently coneluded clinical trial. With ViraNorm’, the Khoday Group is making its entry into the field of science-based alternative medicine.
*ViraNorm’ approved by AYUASH has been developed by the Khoday Group in collaboration with Althea DRF Life Sciences: ViraNorm has undergone one of the largest randomized multicentre phase 3 clinical trials in the country for an Ayurvedic formulation. This trial was conducted in leading institutions like Vietoria hospital, Bengaluru, and was carried out in line with international standards for clinical trials.
ViraNorm’ was developed post extensive safety and efficacy studies, and was found to be effective in the clinical trial” says Dr. Manu Jaggi COO, Althea DRF Lifesciences. *ViraNorm helps halt the progression of virus in the body. “ViraNorm’ can therefore be referred to as an add-on therapy/medication for asymptomatic and mildly symptomatic COVID patients. ViraNorm helps in stopping the migration of the patients from mild to moderate condition.
“Neutrophil- Lymphocyte Ratio (NI R) has increasingly come under spotlight as a very useful, rapid and inexpensive prognostic biomarker for COVID-19 patients. where elevated NLR levels may be associated with unfavourable clinical prognosis. In COVID-19 infections, low NLR levels (ratio range between 0.75-3 is considered as normal) may indicate lower inflammation and higher cytotoxic T cell immunity, and may signify lower COVID-19 viral loads, and may aid in better recovery”, says Dr. Radheshyam Naik, a leading Doctor, and the Prineipal Investigator of the ViraNorm clinical trial.
Human body fights against diseases by showing two types of immunities. One, is antibody mediated immunity. and the other is cell mediated immunity”. The newly developed Ayurvedic medicinal product ViraNorm’ was proven to improve the patients’ cell mediated immunity in the clinical trial, thereby helping patients to recover faster.
Further, it was proven in the clinical trial, that, ViraNorm” also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients. The ingredients in the capsule work by not letting the adhesion of the virus to the cell surface of the individual in nasal or oral cavity regions.
“The reduced NLR ensures reduction in Cellular Level Inflammation and increases Cell Mediated Immunity. This is the only alternative medication which has been systematically proven to reduce NLR in a clinical trial. Since this is developed on fundamental basis of immunity, it may work even for variants of the virus,” says Dr K.G.Padmanaban, who has formulated ViraNorm’.
Human body fights against diseases by showing two types of immunities. One, is *antibody mediated immunity’, and the other is cell mediated immunity. The newly developed Ayurvedic product ViraNorm’ was proven to improve the patients’ cell mediated immunity in the clinical trial, thereby helping patients to recover faster.
Further, it was proven in the clinical trial that ViraNorm’ also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients.
Swamy Khoday Vice Chairman and Managing Director, Khoday Group of Industries says, “ViraNorm‘, which is found to be very effective in clinical trial, and all the technical details are well cireulated.
“I firmly believe that medicines made out of natural ingredients backed by scientific principles will assist in getting cured from ailments and maintain health with no adverse effects”, Swamy points out.
The Clinical Trial for ViraNorm’ was done in Victoria Hospital and other institutions of Bengaluru, which are NABH (National Accreditation Board for Hospitals) accredited. The trial was done with the approval of CTRI (Clinical Trials Registry- India). For this 250 COVID subjects were randomized and enrolled for the trial that lasted for 6 months. These 250 patients were divided into two arms of 125 cach. One group was administered the ViraNorm’ and other was not. After a detailed analysis of the trial it was found, that those who were administered ViraNorm fared better compared to those who were not administered this medicine.
“Very interestingly, this promotion of T cell immunity and reduction of cellular inflammation seems to be in both younger (less than 40 years), as well as older (more than 60 years) patients. While older patients have always been a vulnerable age group, the ongoing 2nd wave of COVID-19 is also affecting younger patients in large numbers and therefore this observation seems important”, says Rajeev Nagi. a leading healthcare industry expert.
The enhanced Cell Immunity plays its role in long term recovery. ‘ViraNorm’ is also safe for patients suffering from comorbidities such as hypertension and diabetes.
ViraNorm‘ is available at LK Wellness Centre (#75, 3rd Cross, Residency Road, Bengaluru- 560025) and can be contacted on 080-40934216/93801 74977. ViraNorm is priced at Rs 2000/- per bottle of 60 capsules.
City Today News 
You must be logged in to post a comment.